Minzhang Chen, Ph.D.
Co-CEO of WuXi AppTec
About Us
The TIDES platform,
end to end.
WuXi TIDES simplifies TIDES drug development by putting discovery, CMC development and the entire manufacturing supply chain under one roof.
WuXi TIDES, a unique Contract Research and Development Manufacturing Organization (CRDMO) platform, is an integral part of WuXi AppTec. WuXi TIDES offers our worldwide partners efficient, flexible, and high-quality solutions for the drug development of oligonucleotides, peptides and related synthetic conjugates (“TIDES” drugs). We greatly simplify the TIDES drug development by providing all discovery, CMC development and the entire manufacturing supply chain under one roof.
WuXi TIDES has over 1,600 scientists from 10 R&D and manufacturing sites, offering discovery synthesis, process development and manufacturing of novel monomers, linkers and ligands, oligonucleotides, peptides and complex synthetic conjugates at any scale. Beyond chemistry, we offer formulation development, manufacturing, packaging, labeling and distribution in a variety of oral & injectable dosage forms and filling formats.
Our comprehensive analytical method development, validation and testing platform supports your TIDES drug development from discovery through clinical to commercial for both drug substance and drug product. Moreover, our regulatory dossier preparation teams are experienced in global filings of TIDES molecules with all major regulatory agencies.
01
Scalability
From discovery to commercialisation entirely within WuXi TIDES, with readily available large R&D and manufacturing capacity.
02
Conjugation Chemistry
Seamless collaboration across the oligonucleotide, peptide and small molecule teams — the conjugates nobody else wants to touch.
03
New Technology
Biocatalysis for gRNA synthesis, thin film evaporation, reactor-in-series with PAT, continuous flow chromatography, TFF.
04
Global Quality Standard
One quality system across every site, approved by the major regulatory agencies around the world.
05
Comprehensive Analytical
Method development and validation, IPC and release testing, characterisation and stability under one roof.
06
Integrated CMC
API and formulation development, manufacturing, analytical, dossier preparation and clinical supply as a single programme.
Global network
Where the work happens.
Ten R&D and manufacturing sites across Asia, Europe and North America — every one of them inside the same quality system.
Shanghai Waigaoqiao, China
Oligonucleotide, Peptide
Changzhou, China
Oligonucleotide, Peptide
Wuxi City, China
Oligonucleotide, Peptide
Taixing, China
Oligonucleotide, Peptide
Wuhan, China
Peptide
Tianjin, China
Oligonucleotide
Chengdu, China
Peptide
Tuas, Singapore
Oligonucleotide, Peptide
Middletown, Delaware, USA
Oligonucleotide, Peptide
Couvet, Neuchâtel, Switzerland
Oligonucleotide, Peptide
Leadership
The people accountable
for your programme.
Senior leadership across manufacturing, development, quality and business operations.
Yu Lu, M.B.A.
Senior Vice President, Head of WuXi TIDES and Business Operations
Jinling Chen, Ph.D.
Senior Vice President, Head of Pharmaceutical Development and Manufacturing
Feng Zhang, M.B.A.
Senior Vice President, Head of API Manufacturing
Dirk Tormans
Senior Vice President, Head Of QA
How can we help?
Our TIDES drug experts stand ready.
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA